C Meschler

[C Meschler @cnmeschler]

@bioinvestor24 @Pharmdca Oooh, thanks for the pic. I get to brush up on my organic chemistry.😎

[C Meschler @cnmeschler]

@SucceededMind @WOLF_Financial Nice idea, except for those of us who get stressed out with timers and deadlines. Just be careful. Listen to how your mind and body respond.

[C Meschler @cnmeschler]

@Banana3Stocks Yes! Yes! Hell yeah!

[C Meschler @cnmeschler]

@crypto_biotech Thank you for as I’ll your hard work. You’ve helped me immensely!❤️

[C Meschler @cnmeschler]

@Jduntrades @TeamBullTrading My daughter and her friend profited way more than we more than we anticipated, due to the incredible generosity from strangers.

[C Meschler @cnmeschler]

@ChartGuys @fundstrat Your 15 minutes of fame! lol

[C Meschler @cnmeschler]

@UmarAshraf Unless your parents were narcissists and thought they were more important than you. I take care of those who chose to do otherwise.

[C Meschler @cnmeschler]

@StockMarketNerd Ditto

[C Meschler @cnmeschler]

@KobeissiLetter @singlesdoubles Thank you, I was getting so confused.

[C Meschler @cnmeschler]

@Banana3Stocks Thank you.

[C Meschler @cnmeschler]

@RealJGBanks Thank you so very much. My adhd makes it so difficult to read books on trading. My brain shuts off and goes somewhere else repeatedly. This is truly a gift.

[C Meschler @cnmeschler]

@crypto_biotech Incredible! So rare to see docs going that far out of their way to get a drug.

[C Meschler @cnmeschler]

@cryptocantoncat @tempo_cap @CatatonicCattt Meeyou, meeyou!

[C Meschler @cnmeschler]

@WOLF_Financial Yes

[C Meschler @cnmeschler]

@cryptocantoncat @dannycheng2022 @matthughes13 @ewtracker Yay! You guys rock!

[C Meschler @cnmeschler]

@ShardiB2 Thank you. I find it so difficult to figure out what makes the market go in any direction, but the more info I get from people like you, the more I can prepare for the “unexpected”movements.

[Pharmdca @Pharmdca]

$VKTX This month and important catalysts into YE2024
1) Full PH2 Venture data for VK2735 very soon. What to expect: Full PK/PD data and likely post last dose follow up data which could provide a rationale for monthly dosing than weekly dosing.

2) FDA meeting notes: A PH2B trial or straight to PH3 trial for VK2735
I believe high possibility for FDA to require VKTX to run a PH2B which CEO also mentioned several times before moving on to PH3 program
➡️➡️If PH2B indeed what company has to run than it gives them an opportunity to explore monthly dosing as well. Roughly 6-9 months timeline

July
We could see oral data for 60mg dose cohort.

Obesity Conference
I believe this is where company likely present full data for all high dose cohorts for oral drug.

Year End 2024
SubQ formulation- Either a PH2B or PH3 to start depending on FDA meeting notes.

[C Meschler @cnmeschler]

@cryptocantoncat You certainly deserve it. I’m envious of your ability to be so prolific and productive.

[C Meschler @cnmeschler]

@MaxOptionsTrade What are the guys gonna wear?